F-star Archives

medical cancer checkpoint inhibitor immunotherapy

News and Trends 29 Apr 2021

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors

Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel immune checkpoint target in nearly a decade. This could herald the next generation of checkpoint inhibitors against cancer. Last month, the antibody drug relatlimab, developed by Bristol Myers Squibb, increased the progression-free survival of melanoma patients in phase III. These […]

April 29, 2021 - 5 minutesmins - By Mark Zipkin

News and Trends 13 Aug 2020

Why are Some European Biotechs Going Public Without an IPO?

European biotech companies are flocking to the Nasdaq Stock Market in 2020, but not all are going the traditional Initial Public Offering (IPO) route. What does this mean for the dominance of the biotech IPO in Europe? In spite of the Covid-19 pandemic, biotech IPOs have continued unabated. In fact, a report from Bioworld found […]

August 13, 2020 - 7 minutesmins - By Jonathan Smith

News and Trends 7 Jun 2017

What Cancer Therapies did European Biotechs Showcase at ASCO 2017?

Here are the most innovative therapies presented by European biotechs fighting cancer during the ASCO 2017 meeting in Chicago. European biotech was in the spotlight during this year’s edition of the American Society of Clinical Oncology (ASCO) meeting, with impressive results from some of the most novel approaches under development to fight multiple forms of cancer. From a […]

June 7, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

C7XeJ78WkAEE Ic 1.jpg large e1490029653662

Interview 20 Mar 2017

Immuno-oncology is Overcrowded – Here is Where Startups Can Succeed

The unprecedented competition in the field represents a daunting challenge for companies trying to break in. A BIO-Europe Panel discussed remaining niches. BIO Europe’s panel on immuno-oncology was perhaps the most popular of the day, as attendees filled the room to hear the thoughts of John Haurum, CEO of F-star; Christophe Quéva, CSO of iTeos; and […]

March 20, 2017 - 3 minutesmins - By Evelyn Warner

Best in Biotech 15 Mar 2017

What are the Best Countries to Recruit Biotech Talents in 2017?

Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look for talent in biotech and had a look at what you can expect from each cluster. For each one of them, we also referenced some data on the biotech, life science and research ecosystems to […]

March 15, 2017 - 10 minutesmins - By External Contributor

Infographics 13 Feb 2017

Infographic: What’s in Europe’s Immuno-oncology Pipeline?

While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer. What new therapies are European biotech cooking up? Since the dawn of immuno-oncology broke with checkpoint inhibitors, innovative therapies like Keytruda and Rituxan from big pharma have taken the world by storm. European biotech’s pipeline is […]

February 13, 2017 - 2 minutesmins - By Evelyn Warner

Best in Biotech 30 Jan 2017

The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge

Cambridge’s image is tied to its Hogwarts-like University and Nobel-hoarding academia, but there’s also an exciting entrepreneurial scene at the cutting edge of technology. We took a look at how big biotech is in the Silicon Fen. Cambridge’s Biotech cluster has an exemplary hive of talent, infrastructure, and capital – enough to create the same vibe […]

January 30, 2017 - 8 minutesmins - By Denise Neves Gameiro

Interview 2 Jan 2017

The Story behind one of the Most Successful Danish Biotech Entrepreneurs

The series of profiles on impressive biotech leaders continues: John Haurum founded one of the most successful biotech companies in Denmark and is now leading one of the hottest European immuno-oncology companies. Here are some of his lessons and thoughts looking back at his rich career. John Haurum, born in Denmark, studied medicine at Aarhus University […]

January 2, 2017 - 6 minutesmins - By Philip Hemme

News and Trends 11 Oct 2016

World Mental Health Day: How is Biotech Helping the Cause?

Biotech is one of the main forces driving the development of effective therapies to treat neurological and mental disorders. For World Mental Health Day yesterday, we want to share with you some of the latest technologies that address these conditions. Yesterday, October 10th, was World Mental Health Day: it is dedicated to raising awareness of neurological and mental disorders […]

October 11, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

jp morgan biotech san francisco california 2016

News and Trends 14 Jan 2016

The Biotech World is Buzzing: J.P. Morgan’s 2016 Phenomenon Kicks off this Week!

Imagine a conference where all the Biotech CEOs and investors of the World come together…all the major players in this Industry, under one roof. That’s basically what the J.P.Morgan Conference is about. Organized by the banking firm of the same name, it is the 34th edition this year. And with age, comes exclusivity: The J.P. […]

January 14, 2016 - 4 minutesmins - By Philip Hemme

f star fcab immunoncology abbvie babraham cancer

News and Trends 13 Jan 2016

UK Biotech starts 2016 by signing a (Massive?) Immuno-Oncology Deal with AbbVie

This year has started with a rush of deals for many Biotechs. F-Star another such company, now signing up for an Immuno-Oncology deal with AbbVie using Bispecific Antibodies. Financial terms were not disclosed but in regards to the hype of the Immuno-Oncology field, it could be pretty high. F-Star is a Cambridge company based at the Babraham […]

January 13, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 3 Nov 2015

Exclusive from BIO-Europe 2015: Interview with F-star, a Cambridge-UK Immuno-oncology Biotech

Second interview of BIO-Europe 2015. This time, it’s a British company from Cambridge (UK): F-star. This morning we spoke with their CBO Jane Dancer. F-star is developing bi-specific antibodies for immuno-oncology and inflammatory disease. It has raised a total of 38 million euros from top EU VCs. Jane Dancer’s business tenure within the field is […]

November 3, 2015 - 1 minutemin - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us